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This study describes the long-term outcome of 33 patients 
with hypertrophic cardiomyopathy who experienced a car- 
diac arrest but were successfully resuscitated. Cardiac 
arrest occurred at ages 9 to 62 years (mean 32); five patients 
survived multiple (two or three) arrests. A variety of 
treatments were administered; 18 patients with left ventric- 
ular outflow tract obstruction underwent ventricular septal 
myotomy-myectomy or mitral valve replacement and also 
received drug therapy; 15 patients received medical ther- 
apy alone. 
To date, 22 (67%) of the 33 patients have survived after 
the initial cardiac arrest for periods of 17 months to 22 
years (mean 7 years); 12 patients have survived for ~5 and 
6 for 210 years. Of the 22 survivors, 16 have remained 
asymptomatic or only mildly symptomatic over the period 
of follow-up: 6 others have become severely symptomatic 
with heart failure, including 3 with evidence of left ventric- 
ular wall thinning and cavity enlargement. Eight patients 
ultimately died of natural cardiac causes (suddenly or of 
progressive heart failure) 7 months to 8.4 years (mean 4 
years) after their initial cardiac arrest. Actuarial patient 
survival was 97 t 3%, 74 + 9% and 61 + 11% after 1, 5 
and 10 years, respectively. Event-free rate (defined as 
actuarial survival without recurrent cardiac arrest or 
death) was 83 + 7%) 65 +- 9% and 53 f 11% , respectively. 
For this group of patients with hypertrophic cardiomy- 
opathy who were treated in a nonsystematic fashion with a 
variety of therapeutic strategies, the long-term outcome 
after surviving a cardiac arrest was variable. Recurrent 
cardiac arrest or premature cardiac death (sudden or due 
to congestive failure) occurred in one-third of the patients, 
most commonly within the first 5 years after the initial 
arrest. Conversely, most patients have survived and re- 
mained free of subsequent cardiac arrest usually without 
experiencing marked symptoms; hence, aborted episodes of 
sudden death do not necessarily convey a uniformly omi- 
nous prognosis in hypertrophic cardiomyopathy and in 
some patients appear to be isolated and unexpected events 
in the natural history of their disease. 
(J Am Co11 Cardiol 1989;13:1283-8) 
Cardiac arrest and sudden death occur not uncommonly in 
patients with hypertrophic cardiomyopathy and constitute 
the most devastating complications of this disease (L-6). 
Occasionally. patients with hypertrophic cardiomyopathy 
experience a cardiac arrest but are successfully resuscitated 
and survive. However. only a few such patients have been 
reported and the long-term clinical outcome is largely un- 
known (7-9). The present study describes a large group of 
patients referred to the National Institutes of Health with 
hypertrophic cardiomyopathy who survived cardiac arrest at 
some time in their clinical course. Our analysis, therefore. 
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affords an opportunity to assess the clinical course and 
consequences of this unique subset of patients with hyper- 
trophic cardiomyopathy. 
Methods 
Selection of patients. The study group comprised all 33 
patients with hypertrophic cardiomyopathy who were re- 
ferred to the National Institutes of Health since 1973 and 
who experienced a documented cardiac arrest from which 
they were successfully resuscitated and subsequently sur- 
vived for 22 months. Cardiac arrest occurred in 26 of the 33 
patients before and in 7 patients after evaluation at the 
National Institutes of Health. 
At some time in their clinical course, each patient dem- 
onstrated by echocardiography the morphologic criteria of 
hypertrophic cardiomyopathy, that is, an asymmetrically 
hypertrophied and nondilated left ventricle in the absence of 
another cardiac or systemic disease that could produce left 
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ventricular hypertrophy (10). Two patients also had mild 
systemic hypertension, two other patients had associated 
cardiac disease that was potentially of clinical importance, 
one had anomalous origin of the left main coronary artery 
from the anterior sinus of Valsalva (6) and one had single 
vessel atherosclerotic coronary artery disease. 
In this investigation, cardiac arrest was defined as the 
circumstance in which a patient experienced sudden and 
unexpected cardiovascular collapse with loss of conscious- 
ness and had electrocardiographic (ECG) documentation of 
ventricular fibrillation (3 1 patients) or asystole (1 patient); in 
1 other study patient, an ECG was not obtained at the time 
of collapse, but the finding that the patient was pulseless 
during cardiopulmonary resuscitation strongly suggested 
that a true cardiac arrest had occurred. 
The clinical status of all 33 study patients was assessed 
most recently as ofJuly I, 1988. At that time (or at the time 
of death) patients ranged in age from 15 to 66 years (mean 
39); the follow-up period from the time of initial cardiac 
arrest was 5 months to 22 years (mean 6 years). 
Echocardiography. Two-dimensional echocardiographic 
studies were performed with either an Advanced Technol- 
ogy Laboratory Mark 500 mechanical sector scanner and a 3 
MHz transducer or a Varian (V-3000 or V-3400) real-time, 
phased array, ultrasound sector scanner (80”) and a 2.25 
MHz transducer. Two-dimensional echocardiographic im- 
ages were recorded in the parasternal long- and short-axis 
and apical views with use of standard transducer positions. 
Extent of left ventricular hypertrophy was assessed from the 
echocardiographic study, using methods previously de- 
scribed in detail (11,12). M-mode echocardiograms were 
recorded with a dedicated Irex System I1 instrument or were 
derived from the two-dimensional image under direct ana- 
tomic visualization. 
Statistical analysis. Life table estimates of patient sur- 
vival were calculated by the actuarial methods of Cutler and 
Ederer (13) and Kaplan and Meier (14) and the probability 
estimates were expressed as the standard error of the mean. 
Results 
Clinical and demographic data. Age at the time of cardiac 
arrest ranged from 9 to 62 years (mean 32). Sixteen of the 33 
patients experienced their cardiac arrest between the age of 
21 and 35 years; 6 were ~20 years old and 6 were >50 (Fig. 
1). Twenty-one patients (64%) were male. 
Seventeen of the 33 study patients had at least one 
relative with definite or probable evidence of hypertrophic 
cardiomyopathy (including 10 with a family member ~50 
years of age who had died suddenly). In the families of the 
other 16 patients, no relative was known to have hypertro- 
phic cardiomyopathy, but systematic echocardiographic 
screening had not been performed in these family members 
(15). 
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Figure 1. Age distribution at time of cardiac arrest in 33 patients 
with hypertrophic cardiomyopathy; solid portions of bars denote the 
11 patients who subsequently died. 
Circumstances of cardiac arrest. At the time of their 
collapse, 14 patients were sedentary (including 3 who were 
hospital in-patients at the time) and 8 were performing mild 
forms of exertion (such as walking). The other 11 patients 
experienced cardiac arrest during or just after running or 
participating in other activities involving severe exertion. 
Clinical Findings Before Cardiac Arrest 
Symptoms. Before cardiac arrest, 13 of the 33 patients 
had no functional limitation (New York Heart Association 
functional class I); 8 of the 13 were virtually asymptomatic, 
but the other 5 had experienced transient and potentially 
important symptoms (syncope in 4 and near-syncope in 1). 
Of the remaining 20 patients, 14 had mild symptoms (class 
II) and 6 had marked symptoms (class III) before cardiac 
arrest; each of these 20 patients had experienced exertional 
dyspnea, 12 had chest pain and 9 had clinically important 
periods of impaired consciousness (4 with true syncope and 
5 with near-syncope). Four of the 33 study patients experi- 
enced symptoms (dyspnea or chest pain) that were consid- 
ered to be prodromal, occurring just minutes or hours before 
the cardiac arrest. 
Arrhythmias. Before the cardiac arrest, seven patients 
had at least one episode of paroxysmal atria1 fibrillation or 
supraventricular tachycardia with a rapid ventricular rate of 
150 to 250 beatsimin that was associated with important 
cardiac symptoms. Each of these episodes occurred in the 
hospital or at a physician’s office in a circumstance where 
the patient was closely observed. In four of these seven 
patients, the supraventricular tachyarrhythmia was docu- 
mented only a few hours before their cardiac arrest (and just 
after a syncopal episode in one patient). 
Medical therapy. Thirteen patients were not taking car- 
dioactive medications at the time of cardiac arrest. The other 
20 patients were taking a variety of such medications, 
including a beta-adrenergic blocking agent alone (propran- 
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0101 or atenolol. 12 patients), verapamil alone (2 patients). 
combined propranolol and verapamil (2 patients), proprano- 
lol and hydrochlorothiazide (1 patient). amiodarone (I pa- 
tient) and digoxin (2 patients). 
In 30 of the 33 patients, adequate cardiopulmonary resus- 
citation was instituted promptly within only a few minutes of 
the cardiovascular collapse. This was possible because of 
fortuitous circumstances in which a physician or another 
person skilled in cardiopulmonary resuscitation, such as a 
nurse or fireman, was either accompanying the patient or 
was in the immediate vicinity at the time of collapse. 
Additionally. a trained emergency rescue unit arrived 
promptly and immediately initiated cardiopulmonary resus- 
citation and electrical cardioversion to 1 I of these 30 pa- 
tients. 
In the other three patients, periods estimated to be >5 
min passed before resuscitation could be instituted; two of 
these individuals were the only patients in the study group 
who incurred permanent neurologic sequelae. 
Echocardiographic data. In 19 patients, two-dimensional 
echocardiograms (obtained 518 months before cardiac ar- 
rest or 4 1 year after arrest) were available and adequate for 
the purpose of characterizing the distribution of left ventric- 
ular hypertrophy. Extent of left ventricular hypertrophy was 
generally marked in the overall patient group. The vast 
majority of patients (17 of 19, 89%) showed diffuse distribu- 
tion of hypertrophy involving both the ventricular septum 
and anterolateral free wall: hypertrophy was limited to the 
anterior ventricular septum in only 2 patients (I 1%). In each 
patient the anterior septum was the site of maximal left 
ventricular wall thickness (range 18 to 40 mm [mean 281). 
Hypertrophy was particularly marked in seven patients who 
had at least one wall segment that was 230 mm thick: four of 
these patients had an extreme form of hypertrophy in which 
three or more segments were 230 mm thick (16). 
Hemodynamic data. Of the 33 patients. 32 underwent 
cardiac Catheterization. Sixteen had obstruction to left ven- 
tricular outflow with a subaortic pressure gradient under 
basal conditions of 60 to 150 mm Hg (average 74). The 
remaining 16 patients had no or a minimal (~30 mm Hg) 
basal outflow gradient: however, 8 of these 16 patients had a 
larger gradient of 40 to 135 mm Hg (average 79) induced by 
provocative interventions (e.g., Valsalva maneuver, amyl 
nitrite inhalation or isoproterenol infusion). One patient with 
a basal subaortic gradient of 105 mm Hg also had a large right 
ventricular outflo& tract gradient of 47 mm Hg. Left ventric- 
ular end-diastolic pressure was 215 mm Hg in 19 patients 
(range 16 to 30, average 23) and <I5 mm Hg in the other 13. 
Clinical Findings After Curdiuc Arrest 
Treatment. Patients were managed with three therapeu- 
tic strategies (Fig. 2). In 15 patients only drugs were given: 
these included an antiarrhythmic agent such as procainamide 
J 
OUTCOME 
Figure 2. Therapeutic strategies and long-term outcome in 33 pa- 
tients with hypertrophic cardiomyopathy xho survived cardiac 
arrest. 
in 5 patients, quinidine in 4, amiodarone in 4, tocainide in I 
and disopyramide in 1 patient: in 10 of these patients. the 
antiarrhythmic drug was taken in combination with propran- 
0101, verapamil. nifedipine or a diuretic. 
Eighteen patients Mith u hnsd or prowktrhle .~uhuortic 
grcrdient 250 mm Hg undem~ent operrttion (septal myotomy- 
myectomy in 17 and mitral valve replacement in I) (17). In I4 
of these patients, operation was performed within 6 months 
of cardiac arrest and then empiric antiarrhythmic therapy 
was administered on a long-term basis except for 2 patients 
who received only verapamil; the antiarrhythmic agent was 
quinidine in 5 patients, procainamide in 3, disopyramide in 3 
and tocainide in 1 patient and was taken in combination with 
either propranolol, verapamil or a diuretic. In the remaining 
four patients, antiarrhythmic therapy (quinidine in three 
patients and disopyramide in one patient) was initiated 
immediately after cardiac arrest for periods of 7 months to 3 
years (mean 1.5 years), after which operation was performed 
and antiarrhythmic therapy continued thereafter. 
Long-term follow-up and survival. Twenty-two (67%) of 
the 33 patients have survived to date for periods of 17 
months to 22 years (mean 7 years) after their cardiac arrest, 
including 12 who have survived for 25 years (6 patients for 
>I0 years). At the most recent clinical evaluation IO of the 
22 survivors were asymptomatic, 6 were mildly symptomatic 
(functional class II) and 6 had marked symptoms (class III or 
IV) (Fig. 3). When the symptomatic status at the most recent 
clinical evaluation of these 22 patients was compared with 
that prior to cardiac arrest. the condition of 6 patients had 
improved, that of 4 had deteriorated and that of 12 was 
unchanged. 
During the follow-up period, 11 patients died: 8 of natural 
cardiac causes. 1 of hepatic cirrhosis, 1 by suicide and 1 
during a diagnostic electrophysiologic study at another insti- 
tution (Fig. 3). The eight patients who ultimately died of 
natural cardiac causes survived 7 months to 8.4 years (mean 
4 years) after their cardiac arrest. In four of these patients 
death was sudden and unexpected and the four other pa- 
tients died of progressive heart failure. each with chronic 
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Figure 3. Clinical state before cardiac arrest and at most recent 
clinical evaluation in 33 patients with hypertrophic cardiomyopathy: 
I, II, III, IV refer to New York Heart Association functional classes; 
CHF = congestive heart failure. 
atria1 fibrillation. The latter four patients had experienced 
severe congestive symptoms after cardiac arrest and subse- 
quently underwent ventricular septal myotomy-myectomy 
(Fig. 2). Outflow obstruction was relieved by surgery in two 
(postoperative basal gradient of 0 and 10 mm Hg, respec- 
tively), one died of heart failure that was due largely to 
surgically induced aortic regurgitation, and the other had a 
residual outflow gradient after myotomy-myectomy (40 mm 
Hg basal; 100 mm Hg provoked). 
Five study patients survived more than one cardiac 
arrest. The second arrest occurred 3 weeks and 5, 6 and 9 
and 40 months, respectively, after the first cardiac arrest. 
Two of these five patients survived a third cardiac arrest 9 
and 33 months, respectively, after the initial arrest. To date, 
three of the five patients with multiple cardiac arrests are still 
alive, whereas one patient died of congestive heart failure 
and one died suddenly. Recurrent catastrophic cardiac 
events (i.e., a second arrest or subsequent sudden cardiac 
death) occurred in 8 (24%) of the 33 patients, 5 in the I st year 
and 1 each at 2, 3 and 6 years after the initial cardiac arrest. 
Only one patient who underwent operation after the initial 
cardiac arrest (with relief of outflow obstruction) later expe- 
rienced a second event or sudden death during the period of 
follow-up. 
Overall actuarial patient survival was 97 2 3%, 74 + 9% 
and 61 2 11% at 1, 5 and 10 years, respectively, after the 
initial cardiac arrest (Fig. 4). When the data were analyzed 
by considering both recurrent cardiac arrest and late death 
(either sudden or due to congestive failure) as a catastrophic 
event, the calculated actuarial freedom from such events 
was 83 ? 7%, 65 t 9% and 53 2 11% at 1, 5 and 10 years, 
respectively (Fig. 4). 
Echocardiographic data. Of the 19 patients with serial 
two-dimensional echocardiograms of adequate technical 
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Figure 4. Actuarial late survival of 33 patients after cardiac arrest. 
The curve has not been extended past IO years because only three 
study patients had been followed up for 211 years (Le., 14, 14 and 
22 years, respectively). 
quality (performed over a period of 9 months to 7 years after 
the initial cardiac arrest), 6 showed a substantial decrease 
(by 7 to 12 mm; mean 10) in the thickness of the anterior 
ventricular septum, and 4 of these had an increase in left 
ventricular end-diastolic dimension of 7 to 20 mm (mean 
change in transverse dimension 39 to 53 mm) (12). Two of 
these six patients remained asymptomatic, but the four 
others developed marked congestive symptoms concomitant 
with this morphologic evolution (including one who died by 
suicide). One of the latter four patients, who had previously 
experienced only mild transient symptoms (7), first incurred 
severe congestive heart failure associated with impaired 
systolic function, left ventricular wall thinning and cavity 
enlargement 21 years after the initial cardiac arrest. 
Discussion 
The present investigation describes a unique and highly 
selected subgroup of 33 patients with hypertrophic cardio- 
myopathy, namely, those who have been successfully resus- 
citated after a cardiac arrest. The vast majority of these 
patients survived their arrest largely because it occurred 
under particularly fortuitous circumstances in the presence 
of trained personnel who could institute cardiopulmonary 
resuscitation almost immediately after collapse. Because 
there are few data previously reported regarding such pa- 
tients, the principal objective of this study was to assess the 
long-term clinical prognosis of this relatively large group of 
patients with hypertrophic cardiomyopathy after their recov- 
ery from cardiac arrest. 
Long-term prognosis. It had been our preconceived bias 
that the prognosis of such patients was highly unfavorable, 
regardless of the therapeutic strategy; that is, once the 
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Figure 5. Clinical outcome in 33 patients with hypertrophic cardio- 
myopathy surviving cardiac arrest. 
proclivity for ventricular fibrillation had been demonstrated 
by a patient, the risk for recurrence of a catastrophic cardiac 
event would necessarily be substantial. This belief was 
based on the data derived from patients with coronary artery 
disease who survived cardiac arrest occurring in the absence 
of associated acute myocardial infarction (18-20). 
Indeed, almost one-fourth of our 33 patients experienced 
(and survived) a second or third cardiac arrest or had sudden 
cardiac death, usually within the 1st year after the initial 
cardiac arrest. In addition, three other patients who did not 
have recurrent cardiac arrest or sudden death ultimately died 
of congestive heart failure 4 to 8 years after their initial 
arrest. Consequently, over an average follow-up period of 6 
years after initial cardiac arrest, one-third of the patients had 
experienced an unfavorable cardiac event or outcome (i.e.. 
recurrent arrest. sudden death or death from progressive 
heart failure) (Fig. 5). On the other hand, almost 60% of the 
patients have survived to date without recurrent cardiac 
arrest (Fig. 5). including 12 patients who have lived for r5 
years (6 of whom have survived for 2 10 years and for up to 
22 years); the majority of these patients have remained 
virtually free of symptoms for prolonged periods of time. 
Therefore, it would appear that in some patients with hyper- 
trophic cardiomyopathy, aborted episodes of sudden death 
do not convey the ominous prognosis that we would have 
intuitively expected. 
Congestive failure after cardiac arrest. Four of eight 
patients who died of cardiac causes did so from progressive 
heart failure rather than suddenly and unexpectedly. The 
precise mechanisms responsible in each of these four deaths 
is uncertain; however, in one, left ventricular volume over- 
load emanating from aortic regurgitation that was iatrogeni- 
tally produced at operation played an important role. On the 
other hand. four other patients in this study group demon- 
strated evidence of the “burned out” phase of hypertrophic 
cardiomyopathy in which progressive heart failure and 
marked clinical deterioration were associated with impaired 
systolic function and left ventricular wall thinning or cavity 
enlargement. or both (12). Although there was a tendency for 
recurrent cardiac arrest or sudden death to occur early (i.e.. 
within the 1st year after initial arrest), congestive heart 
failure deaths and evolution to the “burned out” phase 
occurred much later, >4 years after initial cardiac arrest 
(and 21 years after arrest in one patient). Furthermore, our 
observations underline the fact that individual patients with 
hypertrophic cardiomyopathy may harbor the unique poten- 
tial to experience such widely divergent disease manifesta- 
tions as sudden cardiac collapse and congestive heart failure 
at different times in their clinical course. 
Possible mechanisms of sudden death. Our findings pro- 
vide some additional insights regarding the possible mecha- 
nisms responsible for cardiac arrest in patients with hyper- 
trophic cardiomyopathy (l-6,21). It has been shown that the 
most common predictor for sudden death in this disease is 
ventricular tachycardia observed during ambulatory ECG 
monitoring (22,23). Our observations suggest that supraven- 
tricular tachyarrhythmias may also provide the substrate 
that predisposes to sudden cardiac arrest in some patients 
(8.24-27); seven study patients had such clinically important 
arrhythmias. including four in whom supraventricular tachy- 
arrhythmias occurred just before cardiac arrest. It is uncer- 
tain whether such deterioration of a supraventricular arrhyth- 
mia to ventricular fibrillation is mediated by accessory 
atrioventricular pathways (24,25), hemodynamic decompen- 
sation (25) or, possibly, myocardial ischemia (8,28-31). 
Limitations of the study design. Study patients were re- 
ferred to the National Institutes of Health and evaluated 
over a IS year period. However, these patients were not part 
of a particular standard treatment protocol and, therefore, 
the therapy they received at our institution varied consider- 
ably. For example. most patients with obstruction to left 
ventricular outflow had operation (usually septal myotomy- 
myectomy) as well as drug therapy, but those with the 
nonobstructive form of the disease were treated empirically 
with a variety of cardioactive and antiarrhythmic medica- 
tions given in various combinations and dosages. Therefore. 
it is not possible to derive definitive conclusions from our 
data regarding either the untreated natural history of the 
patients with hypertrophic cardiomyopathy who survive a 
cardiac arrest, or the relative efficacies of the different 
therapeutic strategies employed in these patients. Further- 
more, because type IA antiarrhythmic agents were not 
employed in a standardized fashion in our patients and 
amiodarone was rarely utilized, our study cannot specifically 
address the efficacy of these drugs in patients with hypertro- 
phic cardiomyopathy who survived cardiac arrest. 
Future perspectives. Although 40% of patients in this 
study have survived over the period of follow-up without 
important symptoms or recurrence of cardiac arrest (after 
being treated in a nonsystematic fashion with a variety of 
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modalities), we nevertheless currently favor an aggressive 
approach to this clinical problem. Such strategies involve, in 
most patients if appropriate, electrophysiologic investigation 
and insertion of an automatic implantable cardioverter- 
defibrillator, as well as operation to relieve outflow obstruc- 
tion if an important basal pressure gradient is present. 
Indeed, to date four of our study patients have had an 
automatic defibrillator implanted; one ultimately died of 
congestive heart failure, ,and the follow-up period in the 
other three has been too brief to permit any meaningful 
conclusions. However, we should emphasize that survivors 
of cardiac arrest with hypertrophic cardiomyopathy consti- 
tute a heterogeneous subgroup of patients, and the mecha- 
nisms and predisposing factors underlying their arrest may 
differ greatly. Consequently, no single diagnostic or thera- 
peutic strategy can be applied uniformly, rather, these 
approaches should probably be individualized on the basis of 
pertinent findings of each particular patient. 
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